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Joint Reporting FormIntroduction: The WHO recommends annual influenza vaccination to prevent influenza illness in high-
risk groups. Little is known about national influenza immunization policies globally.
Material and Methods: The 2014 WHO/UNICEF Joint Reporting Form (JRF) on Immunization was adapted
to capture data on influenza immunization policies. We combined this dataset with additional JRF infor-
mation on new vaccine introductions and strength of immunization programmes, as well as publicly
available data on country economic status. Data from countries that did not complete the JRF were sought
through additional sources. We described data on country influenza immunization policies and used
bivariate analyses to identify factors associated with having such policies.
Results: Of 194 WHO Member States, 115 (59%) reported having a national influenza immunization pol-
icy in 2014. Among countries with a national policy, programmes target specific WHO-defined risk
groups, including pregnant women (42%), young children (28%), adults with chronic illnesses (46%),
the elderly (45%), and health care workers (47%). The Americas, Europe, and Western Pacific were the
WHO regions that had the highest percentages of countries reporting that they had national influenza
immunization policies. Compared to countries without policies, countries with policies were significantly
more likely to have the following characteristics: to be high or upper middle income (p < 0.0001); to have
introduced birth dose hepatitis B virus vaccine (p < 0.0001), pneumococcal conjugate vaccine (p = 0.032),
or human papilloma virus vaccine (p = 0.002); to have achieved global goals for diphtheria-tetanus-
pertussis vaccine coverage (p < 0.0001); and to have a functioning National Immunization Technical
Advisory Group (p < 0.0001).
Conclusions: The2014 revisionof the JRFpermitted aglobal assessment ofnational influenza immunization
policies. The 59%of countries reporting that they hadpolicies arewealthier, usemore newor under-utilized
vaccines, and have stronger immunization systems. Addressing disparities in public health resources and
strengthening immunization systems may facilitate influenza vaccine introduction and use.
 2016 Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creative-
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The Global Action Plan for Influenza Vaccines (GAP1) was
launched by the World Health Organization (WHO) in 2006 to
reduce the global shortage of seasonal and pandemic influenza vac-
cines [1]. A major goal of GAP is to increase seasonal influenza vac-
cine use globally. Addressing this goal would prevent severe
influenza illness, strengthen health systems within countries to bet-
ter respond to influenza pandemics, and encourage the vaccine
industry to develop greater influenza vaccine manufacturing capac-
ity [1]. Since the launch of GAP, regional influenza vaccine manufac-
turing capacity has expanded and overall global production capacity
has increased [2–5]. As of 2015, global production capacity for a pan-
demic influenza vaccine is estimated to be around 6.372 billion
doses per year [5]. While this estimate represents a large increase
from the most recent assessment, production capacity is still far
from the GAP goals of being able to provide two doses of vaccine
to 70% of the global population within 6 months [1].
The 2012 WHO position paper on influenza vaccines notes that
influenza causes considerable morbidity worldwide and that coun-
tries should consider implementing influenza vaccine programmes
as national capacities and resources allow [6]. WHO recommends
that countries consider immunizing high-risk groups against
influenza; these groups include pregnant women, young children
6–59 months, adults with specific chronic illnesses, persons at
least 65 years, and health care workers [6]. As of the 2012 position
paper, WHO recommends that countries initiating or expanding
influenza immunization programmes should prioritize pregnant
women, while other risk groups are not ranked by priority [6].
There are limited published data about the presence or nature of
national influenza immunization policies in many countries. We
reviewed data reported by Member States to WHO and UNICEF
to evaluate national influenza immunization priorities and use to
inform efforts to meet WHO influenza immunization goals [1,7].2. Materials and methods
We adapted the WHO/UNICEF Joint Reporting Form on Immu-
nization (JRF) to include questions on national influenza immu-
nization policies and use. Since 1998, the JRF is completed
annually by Ministries of Health of WHO Member States [8]. The
JRF is a monitoring and evaluation tool that collects nationalNonstandard abbreviations used in text:
 AFR: WHO Africa Region
 AMR: WHO Region of the Americas
 DTP3: third dose of diphtheria-tetanus-pertussis vaccine
 EMR: WHO Eastern Mediterranean Region
 EUR: WHO Europe Region
 GAP: Global Action Plan for Influenza Vaccines
 JRF: WHO/UNICEF Joint Reporting Form on Immunization
 MNTE: maternal and neonatal tetanus elimination
 NITAG: National Immunization Technical Advisory Group
 SEAR: WHO South-East Asia Region
 UNICEF: United Nations Children’s Fund
 WPR: WHO Western Pacific Regionadministrative information regarding estimates of immunization
coverage, reported cases of vaccine-preventable diseases, immu-
nization schedules, vaccination campaigns, as well as indicators
of immunization system performance and financing [9]. Most
WHO Member States report immunization data annually in the
JRF. Prior to 2014, the JRF collected information about influenza
vaccine schedules, distribution, and coverage. At that time, WHO
adapted the influenza vaccine JRF questions to focus on presence
of seasonal influenza immunization policies during the preceding
year, 2014 (see Table 1). Collected data included whether the coun-
try had a national seasonal influenza vaccination policy, the groups
targeted for vaccination by the policy, the influenza vaccine formu-
lation used (northern or southern hemisphere), and the number of
influenza vaccine doses distributed. Vaccine distribution data are
collected as an approximate measure of vaccine use, since data
on doses administered are not available in many countries. Influ-
enza vaccine coverage among persons with chronic illnesses and
among the elderly are also collected to monitor progress toward
World Health Assembly resolution WHA56.19 goals that countries
with influenza vaccine programmes immunizeP 75% of persons in
these groups [7]. The entire JRF undergoes standard data checks at
national, regional, and global levels to improve data quality and
consistency. We reviewed the specific JRF influenza vaccine data.
We used regional surveys from the Americas, Europe, and the
Western Pacific to determine the presence of immunization poli-
cies for some countries that did not report influenza data on the
JRF [10–14]. We did not extract vaccine coverage, formulation, or
distribution data from non-JRF sources. We used the 2014 JRF
database that was available as of 15 July 2016.
Next, we identified additional Member-State-specific data (from
2014 except where noted) that were relevant to immunization pro-
grammes (Table 4). As a measure of country economic status, we
used 2013World Bank data for country income category and health
expenditure per capita [15]. As low-resource countries often rely on
financial support from Gavi, the Vaccine Alliance, for new vaccine
introduction, we also used JRF data for country eligibility to receive
such support (Gavi eligible) [16,17]. To assess newvaccine introduc-
tions, we used JRF data indicating the inclusion of the following vac-
cines in national immunization schedules per WHO
recommendations: birth dose hepatitis B vaccine (HBV), pneumo-
coccal conjugate vaccine (PCV), human papilloma virus vaccine
(HPV), and rotavirus vaccine [18–20]. To assess the general strength
of routine immunizationwe used JRF data indicatingwhether coun-
trieshadachievedGlobalVaccineActionPlan (GVAP)goals ofmater-
nal and neonatal tetanus elimination (MNTE) (<1 case of neonatal
tetanus per 1,000 live births in every district of a country), and we
used theWHOUNICEF estimates of national immunization coverage
to assess if countries had achieved global goals of diphtheria-
tetanus-pertussis containing vaccine third dose coverage (DTP3)
P95% nationally [21,22]. Finally, to assess the strength of a country
to make decisions about vaccine interventions, we used JRF data to
determine whether countries achieved the indicators defining
well-functioningNational ImmunizationTechnicalAdvisoryGroups
(NITAGs) [21,23].We did not have data regardingwhether a country
participated in a well-functioning subregional Technical Advisory
Group (TAG), which is recommended as an option for small coun-
tries. Country income category (high income/upper middle income
Table 1
2014 WHO/UNICEF Joint Reporting Form (JRF) on immunization influenza vaccine
questions.
Does the country have a national seasonal influenza vaccination policy?
Which risk groups if any, are recommended for seasonal influenza
vaccination?
 Children (if yes, specify age range in comment field)
 Older persons (if yes, specify age range in comment field)
 Chronic illness (paediatric)
 Chronic illness (adult)
 Pregnant women
 Health care workers
 Hajj or other travellers
 Any other risk group (if yes, please specify in the comment field)
 All persons > 6 months are recommended to receive vaccine
 No groups are specified for influenza vaccine receipt
How many doses of seasonal influenza vaccine were distributed in 2014?
What seasonal influenza vaccine formulation was used in 2014?
What was the percentage (%) of elderly persons immunized against influenza
in 2014?
What was the percentage (%) of persons with underlying disease immunized
against influenza in 2014?
5402 J.R. Ortiz et al. / Vaccine 34 (2016) 5400–5405vs. lower middle income/low income), new vaccine introduction,
routine immunization, and NITAG covariates were defined as
dichotomous variables for statistical analyses.
We used descriptive statistics to describe JRF responses globally
among all 194 WHO Member States and within the six WHO
regions: Africa (AFR), 47 countries; Americas (AMR), 35 countries;
Eastern Mediterranean (EMR), 21 countries; Europe (EUR), 53
countries; South-East Asian (SEAR), 11 countries; and Western
Pacific (WPR), 27 countries [24]. Our analysis excluded non-
Member States and territories. We conducted bivariate analyses
to compare covariate association with presence of a national influ-
enza immunization policy using v2 for categorical variables and
Wilcoxon-Mann-Whitney test for non-parametric continuous vari-
ables. All statistical tests were two sided, and p-values < 0.05 were
considered statistically significant. Missing data were excluded
from analyses. We used Stata statistical software version 14.0
(StataCorp; College Station, TX, United States of America). As weTable 3
WHO Member States with influenza immunization policies in 2014, by country income st












Low and lower-middle income
countries that are GAVI-eligible
49 4 (8%) 1 (2%) 2
Low and lower-middle income
countries that are not GAVI-eligible
34 16 (47%) 7 (21%) 1
Upper middle income countries 52 41 (79%) 19 (37%) 2
High income countries 59 54 (92%) 26 (44%) 4
Notes: Data source is 2014 WHO/UNICEF Joint Reporting Form (JRF) augmented by polic
Table 2
WHO Member States with influenza immunization policies in 2014, by WHO region.






Africa (AFR) 47 3 (6%) 2 (4%)
Americas (AMR) 35 31 (88%) 22 (63%)
Eastern Mediterranean (EMR) 21 12 (57%) 6 (29%)
Europe (EUR) 53 51 (96%) 12 (23%)
South-East Asian (SEAR) 11 2 (18%) 2 (18%)
Western Pacific (WPR) 27 16 (59%) 8 (30%)
Worldwide 194 115 (59%) 54 (28%)
Notes: Data source is 2014 WHO/UNICEF Joint Reporting Form (JRF) augmented by policused publicly available, national-level data collected for monitor-
ing and evaluation of public health programmes, no human sub-
jects approval was needed.3. Results
Of 194 WHO Member States, 187 (96%) submitted a 2014 JRF to
WHO and UNICEF and 162 (84%) provided data regarding influenza
immunization policies in the JRF. Data were reported from each
WHO region, including AFR (100%), AMR (91%), EMR (81%), EUR
(74%), SEAR (100%), and WPR (63%). After review of other pub-
lished sources [10,11,13,14], we were able to identify influenza
immunization policy information for 189 (97%) Member States.
Of the 194 WHO Member States, 115 (59%) countries reported
having a national influenza immunization policy (Fig. 1, Table 2).
No country reported that it had a national policy to not use
influenza vaccine. Among the countries with a national policy,
immunization programmes targeted specific WHO-defined risk
groups, including pregnant women (42%) (Fig. 2), young children
(28%), adults with chronic illnesses (46%), the elderly (45%), and
health care workers (47%). Fifteen percent of countries that
reported national policies targeted all persons > 6 months for
immunization with influenza vaccine. Among countries with poli-
cies, many targeted additional groups for immunization, including
children with chronic illnesses (if all children were not already tar-
geted to receive vaccine) (15%) and Hajj or other travellers (18%).
There were national influenza immunization policies in countries
classified as high income (92%), upper middle income (79%), lower
middle income (37%), and low income (3%). The number and per-
centage of countries in WHO regions that reported having influ-
enza immunization policies are: 3 (6%) in AFR, 31 (88%) in AMR,
12 (57%) in EMR, 51 (96%) in EUR, 2 (18%) in SEAR, and 16 (59%)
in WPR (Table 2). The proportion of countries with policies
targeting specific risk groups was similar among regions. Of the
16 countries that manufacture influenza vaccines [5], 14 (88%)















(4%) 2 (4%) 2 (4%) 2 (4%) 1 (2%)
0 (29%) 9 (26%) 14 (41%) 11 (32%) 8 (24%)
8 (54%) 26 (50%) 30 (58%) 24 (46%) 16 (31%)
9 (83%) 44 (75%) 45 (76%) 50 (85%) 37 (63%)














3 (6%) 3 (6%) 3 (6%) 3 (6%) 2 (4%)
20 (57%) 21 (58%) 23 (66%) 18 (51%) 14 (40%)
11 (52%) 8 (38%) 10 (48%) 9 (43%) 12 (57%)
33 (63%) 34 (64%) 37 (70%) 39 (74%) 29 (55%)
2 (18%) 2 (18%) 2 (18%) 2 (18%) 2 (18%)
12 (44%) 12 (44%) 15 (56%) 15 (56%) 8 (30%)
89 (46%) 81 (42%) 91 (47%) 87 (45%) 62 (32%)
y data from regional surveys [10,11,13,14].
Fig. 1. World Map with WHO Member States Reporting to Have a National Seasonal Influenza Vaccine Programme in 2014. Note: The boundaries and names shown and the
designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country,
territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate borderlines for which
there may not yet be full agreement. WHO 2016. All rights reserved. Source: WHO-UNICEF Joint Reporting Forms (JRFs) 2014. Map production: Immunization Vaccines and
Biologicals, (IVB). World Health Organization. Date of slide: 15 July 2016.
Table 4
Comparison of WHO Member States with and without national influenza immunization policies in 2014.
Countries with a national influenza immunization
policy n,%
Countries without a national influenza immunization
policy n,%
Total countries 115 79
Country wealth
Median per capita health expenditure (USD$), (IQR) 664 (342, 2018) 82 (42, 178)
World Bank income category
High income 54 (47%) 5 (6%)
Upper middle income 41 (36%) 11 (11%)
Lower middle income 19 (17%) 33 (42%)
Low income 1 (1%) 30 (38%)
Gavi-eligible 4 (3%) 45 (57%)
New and Under-utilized vaccine introduction
Introduced birth dose hepatitis B vaccine (HBV) 78 (68%) 29 (37%)
Introduced pneumococcal conjugate vaccine (PCV) 80 (70%) 43 (54%)
Introduced human papilloma virus vaccine (HPV) 56 (49%) 7 (9%)
Introduced rotavirus vaccine 45 (39%) 30 (38%)
Strength of immunization systems
Functioning National Immunization Technical
Advisory Group
61 (53%) 17 (22%)
Eliminated maternal and neonatal tetanus 113 (98%) 57 (72%)
DTP3 coverage P95% nationally 96 (83%) 33 (42%)
Note: Data on influenza immunization policies, functional NITAGs, maternal neonatal tetanus elimination, DTP3 coverage, and MCV2 coverage from 2014 WHO/UNICEF Joint
Reporting Form (JRF) and augmented by policy data from regional surveys [10,11,13,14]. Average per capita health expenditure and income category data are fromWorld Bank.
J.R. Ortiz et al. / Vaccine 34 (2016) 5400–5405 5403Eighty-nine (46%) countries provided information onvaccine for-
mulation used, and of these, 60 (67%) used the northern hemisphere
formulation, 19 (21%) used the southern hemisphere formulation,
and 10 (11%) used both formulations. Sixty-six (34%) countries pro-vided vaccine distribution data. These countries reported distribut-
ing of 230,258,405 doses of seasonal influenza vaccine, or around
37% of the estimated 620 million doses produced annually [4]. Vac-
cine doses were distributed in EUR (39%), AMR (29%), WPR (28%),
Fig. 2. World Map with WHO Member States Reporting to Have a National Seasonal Influenza Vaccine Programme that Targets Either All Persons > 6 Months or Pregnant
Women in 2014. Note: The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the
World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
Dotted lines on maps represent approximate borderlines for which there may not yet be full agreement. WHO 2016. All rights reserved. Source: WHO-UNICEF Joint
Reporting Forms (JRFs) 2014. Map production: Immunization Vaccines and Biologicals, (IVB). World Health Organization. Date of slide: 15 July 2016.
5404 J.R. Ortiz et al. / Vaccine 34 (2016) 5400–5405SEAR (1%), AFR (1%), and EMR (1%). Data were missing from 128
countries (56%), including countries that reported elsewhere tohave
high influenza vaccine distribution rates [25].
A small number of countries reported influenza vaccine
coverage that meets World Health Assembly resolution goals to
immunizeP 75% of persons with chronic underlying diseases
and the elderly. Twenty-five countries (13%) reported influenza
immunization rates in persons with chronic diseases; among these,
coverage ranged from 4% to 100%, and 5 countries (3%) reported
achieving coverageP 75%. Thirty-seven countries (19%) reported
influenza immunization rates in the elderly; among these, cover-
age ranged from 1% to 100%, and only 2 countries (1%) reported
achieving coverageP 75%.
Countries reporting national influenza immunization policies
were significantly more likely to be high income or upper middle
income classification (83% vs 20%, p < 0.0001) and to be ineligible
for Gavi funding support (3% vs 57%, p < 0.0001). Countries with
policies also had significantly higher median per capita health
expenditures than those without such policies (664 USD vs 82
USD, p < 0.0001) (Table 2). In addition, countries with policies were
significantly more likely to have introduced birth dose HBV vaccine
(68% vs 37%, p < 0.0001), introduced PCV vaccine (70% vs. 54%,
p = 0.032), introduced HPV vaccine (49% vs. 9%, p = 0.002), and to
have a functioning NITAG (53% vs. 22%, p < 0.0001). Introduction
of rotavirus vaccine was not significantly associated with influenza
immunization policies. Countries with policies were more likely to
have eliminated neonatal tetanus (98% vs 72%, p < 0.0001) and to
have achieved DTP3 coverageP 95% nationally (83% vs 42%,p < 0.0001). Only four countries with influenza immunization poli-
cies were Gavi-eligible (Table 3); of these, two had functioning
NITAGs, three had introduced birth dose HBV vaccine, one had
introduced PCV vaccine, one had introduced HPV vaccine as a
demonstration project, and none had introduced rotavirus vaccine.
4. Discussion
The 2014 revision of the WHO/UNICEF JRF on Immunization
permitted a global summary of national influenza immunization
policies. Such policies were reported by 59% of WHO Member
States, including countries from all WHO regions and all World
Bank income categories. Our report shows increased global influ-
enza immunization policy development. A 2006 global survey
identified 74 countries and territories with seasonal influenza
immunization policies [26]. That survey of countries and territories
was conducted by WHO as part of the 2006 GAP launch and
achieved a 70% response rate. We identified 115 WHO Member
States with influenza immunization policies in 2014. Since 2006,
policy development was seen in each WHO region, and the coun-
tries targeting pregnant women for influenza vaccine receipt has
increased from around 15 in 2006 to 81 in 2014. Annual reporting
by countries with the JRF will facilitate continued monitoring of
progress of influenza immunization policy development.
This reporthighlights thatworkmust still bedone to ensure equi-
table access of influenza vaccines globally. The regions with the
highest percentages ofMember Stateswith influenza immunization
policies (AMR, EUR, andWPR) reported distributing 97% of all influ-
J.R. Ortiz et al. / Vaccine 34 (2016) 5400–5405 5405enzavaccines.Whilewehad lowresponse rates for influenzavaccine
distribution, the proportion of vaccine distribution byWHO regions
are similar to previous reports using more robust distribution data
by the International Federation of Pharmaceutical Manufacturers
& Associations [25]. Further, 42% of countries reported having speci-
fic programmes for immunization of pregnant women, a risk group
prioritized for influenza vaccine receipt by WHO beginning in
2012. Finally, few countries reportedmeetingWorld Health Assem-
bly goals to immunizeP 75% of elderly persons andP 75% of per-
sons with chronic illnesses [7], though other data sources indicate
more countries have achieved these goals [10,11].
Findings from this survey may facilitate the initiation or expan-
sion of influenza vaccine programmes globally. Countries in higher
World Bank income categories were significantly more likely to
have influenza immunization policies. Other factors associated
with presence of influenza immunization policies included experi-
ence introducing other new and under-utilized vaccines such as
birth dose HBV vaccine, PCV, and HPV. Countries with influenza
immunization policies had strong routine immunization pro-
grammes as measured by DTP3 coverage as well as by achieving
elimination of maternal and neonatal tetanus. Many countries
without influenza policies did not have functional NITAGs.
Strengthening NITAGs to support review of evidence to make vac-
cine recommendations is critical for country decision making.
Lastly, the lack of financing mechanisms to support influenza vac-
cine introduction in low-resource countries will pose a major chal-
lenge. Knowledge of the factors that influenced the development of
influenza immunization policies would be of high value for efforts
to increase influenza vaccine use globally.
The report should be interpreted in the context of several limi-
tations. Data were collected from the first year that influenza
immunization policy questions were asked in the JRF. WHO expe-
rience with the JRF is that completeness and accuracy of reported
data increases over time with increased familiarity with the form.
The JRF had a substantial amount of missing data on influenza vac-
cines, particularly regarding vaccine distribution and coverage
estimates. Some countries that have made progress achieving
influenza vaccine coverage goals or distributing influenza vaccines
did not provide these data in the JRF. Improving influenza vaccina-
tion monitoring and reporting will be vital if the JRF is to be used to
monitor progress in influenza vaccine use prospectively. Addition-
ally, some countries, mostly high income countries from the Amer-
icas and Europe, did not report influenza vaccine information,
requiring us to seek relevant policy data through reviews of public
information. Finally, the presence of an influenza immunization
policy does not necessarily correlate with substantial vaccine use.
The JRF is an efficient and very useful tool to prospectively mon-
itor annual progress toward implementation and equitable use of
influenza vaccines globally. WHO recommends annual vaccination
of high-risk groups to prevent complications of influenza virus
infection, however this report demonstrates that many countries
do not yet have national influenza immunization policies. Coun-
tries without influenza immunization policies tend to have fewer
resources, use fewer new or under-utilized vaccines, and have
weaker routine immunization systems. Addressing these chal-
lenges may facilitate influenza vaccine introduction and use.
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